UBS Group’s Adicet Bio ACET Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $261K | Buy |
38,368
+34,571
| +910% | +$259K | ﹤0.01% | 6486 |
|
|
2025
Q4 | $32K | Buy |
3,797
+2,457
| +183% | +$27.2K | ﹤0.01% | 7489 |
|
|
2025
Q3 | $17.4K | Buy |
1,340
+183
| +16% | +$2.16K | ﹤0.01% | 8249 |
|
|
2025
Q2 | $11.3K | Sell |
1,157
-2,845
| -71% | -$30K | ﹤0.01% | 8791 |
|
|
2025
Q1 | $48.3K | Sell |
4,002
-8,700
| -68% | -$124K | ﹤0.01% | 7626 |
|
|
2024
Q4 | $196K | Buy |
12,702
+10,102
| +389% | +$191K | ﹤0.01% | 6461 |
|
|
2024
Q3 | $59.9K | Sell |
2,600
-7,452
| -74% | -$167K | ﹤0.01% | 6697 |
|
|
2024
Q2 | $195K | Buy |
10,052
+6,706
| +200% | +$180K | ﹤0.01% | 5673 |
|
|
2024
Q1 | $126K | Buy |
3,346
+1,935
| +137% | +$80K | ﹤0.01% | 6118 |
|
|
2023
Q4 | $42.7K | Buy |
1,411
+1,140
| +421% | +$24.9K | ﹤0.01% | 6635 |
|
|
2023
Q3 | $5.94K | Buy |
271
+269
| +13,450% | +$9.5K | ﹤0.01% | 7331 |
|
|
2023
Q2 | $66 | Buy |
+2
| New | +$177 | ﹤0.01% | 8567 |
|
|
2023
Q1 | – | Sell |
-7,349
| Closed | -$1.05M | – | 9531 |
|
|
2022
Q4 | $1.05M | Buy |
7,349
+6,270
| +581% | +$1.56M | ﹤0.01% | 4031 |
|
|
2022
Q3 | $246K | Buy |
+1,079
| New | +$274K | ﹤0.01% | 4909 |
|
|
2022
Q2 | – | Sell |
-34
| Closed | -$11K | – | 10235 |
|
|
2022
Q1 | $11K | Sell |
34
-584
| -94% | -$134K | ﹤0.01% | 8279 |
|
|
2021
Q4 | $173K | Buy |
618
+608
| +6,080% | +$104K | ﹤0.01% | 5824 |
|
|
2021
Q3 | $1K | Buy |
+10
| New | +$1.24K | ﹤0.01% | 9127 |
|
|
2021
Q2 | – | Sell |
-106
| Closed | -$22K | – | 9332 |
|
|
2021
Q1 | $22K | Buy |
106
+70
| +194% | +$16.1K | ﹤0.01% | 7278 |
|
|
2020
Q4 | $8K | Sell |
36
-52
| -59% | -$10.7K | ﹤0.01% | 7605 |
|
|
2020
Q3 | $17K | Buy |
88
+4
| +5% | +$1.01K | ﹤0.01% | 6431 |
|
|
2020
Q2 | $20K | Buy |
84
+48
| +133% | +$9.43K | ﹤0.01% | 6548 |
|
|
2020
Q1 | $4K | Sell |
36
-5,464
| -99% | -$811K | ﹤0.01% | 7365 |
|
|
2019
Q4 | $918K | Buy |
5,500
+5,433
| +8,109% | +$2.75M | ﹤0.01% | 4298 |
|
|
2019
Q3 | $67K | Buy |
67
+63
| +1,575% | +$70.3K | ﹤0.01% | 6019 |
|
|
2019
Q2 | $5K | Sell |
4
-12
| -75% | -$10.9K | ﹤0.01% | 7360 |
|
|
2019
Q1 | $12K | Sell |
16
-8
| -33% | -$7.27K | ﹤0.01% | 6677 |
|
|
2018
Q4 | $23K | Buy |
24
+3
| +14% | +$3.95K | ﹤0.01% | 6663 |
|
|
2018
Q3 | $35K | Buy |
21
+7
| +50% | +$9.13K | ﹤0.01% | 6424 |
|
|
2018
Q2 | $14K | Buy |
+14
| New | +$15.1K | ﹤0.01% | 6928 |
|
Other funds holding ACET
RCM
O
VCM
WP
PM
SCM
UBS Group's ACET Position: Q1 2026 in Review
UBS Group increased its Adicet Bio (ACET) stake by 910% in Q1 2026, buying an estimated $259K and bringing the position to 38,368 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #6486.
UBS Group first reported a position in ACET in Q2 2018 and has held it in 29 quarters since. The position peaked at $1.05M in Q4 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.
- UBS Group held 38,368 shares of Adicet Bio worth $261K as of Q1 2026.
- UBS Group bought 34,571 Adicet Bio shares in Q1 2026, an estimated $259K.
- Adicet Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6486 holding.
- UBS Group first reported a position in Adicet Bio in Q2 2018 and has held it in 29 quarters since.
- UBS Group's Adicet Bio position peaked at $1.05M in Q4 2022.
- 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.